Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 6Small Cell Lung Carcinoma 2Triple Negative Breast Neoplasms 1Intracranial Germ Cell CNS Tumor, Childhood 1Carcinoma, Neuroendocrine 1

Interventions

Everolimus 7Nivolumab 6Cisplatin 6Temozolomide 5Bevacizumab 5lutetium Lu 177 dotatate 4Fluorouracil 4Carboplatin 4pembrolizumab 3avelumab 3atezolizumab 3Irinotecan 3Ipilimumab 3Etoposide 3Capecitabine 3surufatinib 2sintilimab 2gallium Ga 68 dotatate 2dostarlimab 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2PE regimen 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Magnetic Resonance Imaging 2Immunoglobulin G 2IFL protocol 2Fluorodeoxyglucose F18 2Drug Therapy 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Neuroendocrine × EC regimen × Clear all
NCT03992911 2019-06-20

Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

Peking University

Phase 2/3 Unknown
336 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡